First Time Loading...

Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 24.87 USD -1.47% Market Closed
Updated: Jun 16, 2024
Have any thoughts about
Beam Therapeutics Inc?
Write Note

Beam Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beam Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Beam Therapeutics Inc
NASDAQ:BEAM
Capital Expenditures
-$33.7m
CAGR 3-Years
-27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$795m
CAGR 3-Years
3%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$581m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$998m
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$464.7m
CAGR 3-Years
-14%
CAGR 5-Years
-41%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$809.1m
CAGR 3-Years
-13%
CAGR 5-Years
-16%
CAGR 10-Years
-15%

See Also

What is Beam Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-33.7m USD

Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Capital Expenditures amounts to -33.7m USD.

What is Beam Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-21%

Over the last year, the Capital Expenditures growth was 31%. The average annual Capital Expenditures growth rates for Beam Therapeutics Inc have been -27% over the past three years , -21% over the past five years .